건선성 관절염 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약제 클래스별, 투여 경로별, 지역별, 경쟁별(2020-2030년)

Psoriatic Arthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,403,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,827,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,384,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 건선성 관절염 치료 시장은 2024년에 97억 8,000만 달러로 평가되며, 2030년에는 CAGR 5.69%로 134억 8,000만 달러에 달할 것으로 예측됩니다.

그 배경에는 의약품 개발의 발전, 질병에 대한 인식 증가, 진단 능력의 향상 등이 있습니다. 전 세계 의료 시스템이 건선성 관절염이 삶의 질과 생산성에 미치는 영향을 점점 더 많이 인식하고 있으며, 환자의 진화하는 요구에 부응하기 위해 치료 옵션이 확대되고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	97억 8,000만 달러
시장 규모 : 2030년	134억 8,000만 달러
CAGR : 2025-2030년	5.69%
급성장 부문	NSAI Ds
최대 시장	북미

생물제제는 염증을 억제하고 관절 장애를 예방하는 표적화된 접근법을 제공함으로써 이 시장에서 치료의 핵심이 되고 있습니다. 이러한 치료법은 중등도에서 중증의 환자에게 특히 효과적이며, 선진국과 신흥 국가 모두에서 널리 채택되고 있습니다. 혁신은 계속해서 이 시장 전망를 형성하는 중요한 요소입니다. 제약사들은 안전성 프로파일 개선, 투약 횟수 감소, 환자 순응도 향상을 위한 차세대 치료법에 투자하고 있습니다.

주요 시장 성장 촉진요인

헬스케어 산업의 성장

주요 시장 이슈

높은 치료비와 경제적 접근성

주요 시장 동향

생물제제와 표적 치료의 부상

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 COVID-19가 세계의 건선성 관절염 치료 시장에 미치는 영향

제5장 세계의 건선성 관절염 치료 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 약제 클래스별(NSAIDs, DMARDs, 생물제제, 기타)
  • 투여 경로별(국소, 경구, 주사)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 건선성 관절염 치료 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 건선성 관절염 치료 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 건선성 관절염 치료 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 건선성 관절염 치료 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 건선성 관절염 치료 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병과 인수
• 제품 출시
• 최근 동향

제13장 혼란 : 분쟁, 팬데믹, 무역장벽

제14장 세계의 건선성 관절염 치료 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제16장 경쟁 구도

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Pfizer, Inc.
• UCB S.A.

제17장 전략적 제안

제18장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

Global Psoriatic Arthritis Treatment Market was valued at USD 9.78 Billion in 2024 and is expected to reach USD 13.48 Billion by 2030 with a CAGR of 5.69%. This is driven by advancements in drug development, rising disease awareness, and improvements in diagnostic capabilities. As healthcare systems around the world increasingly recognize the impact of psoriatic arthritis on quality of life and productivity, treatment options are expanding to meet the evolving needs of patients.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 9.78 Billion
Market Size 2030	USD 13.48 Billion
CAGR 2025-2030	5.69%
Fastest Growing Segment	NSAI Ds
Largest Market	North America

Biologic therapies remain the cornerstone of treatment in this market, offering targeted approaches that help control inflammation and prevent joint damage. These therapies are particularly effective for patients with moderate to severe disease and have become widely adopted in both developed and emerging regions. Innovation continues to be a critical factor in shaping the future of this market. Pharmaceutical companies are investing in next-generation therapies that offer improved safety profiles, reduced dosing frequency, and enhanced patient adherence.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry is playing a pivotal role in driving the growth of the psoriatic arthritis treatment market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. The most substantial and profitable segments within the sector are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which generate over USD 400 billion. With increasing investments in healthcare infrastructure, rising patient awareness, and improved access to specialized care, the demand for effective treatment solutions for chronic autoimmune conditions like psoriatic arthritis is steadily rising.

As healthcare systems across both developed and emerging markets evolve, there is greater emphasis on early diagnosis, personalized medicine, and long-term disease management. More than 200,000 Ayushman Arogya Mandirs have been established nationwide to support early diagnosis and treatment. These centers provide millions of citizens with convenient access to screenings for diseases such as cancer, hypertension, and diabetes. This shift is particularly significant for psoriatic arthritis, a complex and progressive condition that requires comprehensive and sustained treatment strategies. The availability of advanced biologics, targeted therapies, and disease-modifying anti-rheumatic drugs (DMARDs) has expanded significantly as part of this healthcare evolution.

Key Market Challenges

High Treatment Costs & Financial Accessibility

One of the foremost challenges confronting the Global Psoriatic Arthritis (PsA) Treatment Market is the high cost associated with advanced therapies, particularly biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). These innovative treatments, while clinically effective, command significant pricing often reaching tens of thousands of dollars annually per patient. This elevated cost structure poses substantial barriers to patient access, especially in emerging economies and underfunded healthcare systems.

The financial burden not only limits market penetration but also affects patient adherence and long-term treatment outcomes. Payers and insurers are increasingly scrutinizing reimbursement criteria, imposing stringent prior authorization processes that further complicate access. Consequently, patients may experience delays or outright denial of coverage for these essential therapies.

Key Market Trends

Rise of Biologics & Targeted Therapies

The global psoriatic arthritis treatment landscape is witnessing a significant transformation driven by the rapid adoption of biologics and targeted therapies. These advanced treatment modalities have emerged as the cornerstone of disease management, owing to their ability to specifically target underlying inflammatory pathways with enhanced efficacy and safety profiles compared to conventional therapies.

Biologics, including tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17, and IL-23 inhibitors, currently command a substantial share of the market, reflecting their growing acceptance among clinicians and patients alike. In June 2025, Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili (aflibercept). Yesafili, a biosimilar to Eylea (aflibercept) injection, is available in vial and prefilled syringe formats at a concentration of 2 mg/0.05 mL. This marks the first approval by Health Canada of a biosimilar to Eylea. Their precision mechanism of action not only improves clinical outcomes but also contributes to better quality of life for patients suffering from psoriatic arthritis.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Pfizer, Inc.
• UCB S.A.

Report Scope

In this report, the Global Psoriatic Arthritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriatic Arthritis Treatment Market, By Drug Class:

• NSAIDs
• DMARDs
• Biologics
• Others

Psoriatic Arthritis Treatment Market, By Route of Administration:

• Topical
• Oral
• Injectable

Psoriatic Arthritis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriatic Arthritis Treatment Market.

Available Customizations:

Global Psoriatic Arthritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Psoriatic Arthritis Treatment Market

5. Global Psoriatic Arthritis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (NSAIDs, DMARDs, Biologics, Others)
  • 5.2.2. By Route of Administration (Topical, Oral, Injectable)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Psoriatic Arthritis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psoriatic Arthritis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
  • 6.3.2. Mexico Psoriatic Arthritis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
  • 6.3.3. Canada Psoriatic Arthritis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration

7. Europe Psoriatic Arthritis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Psoriatic Arthritis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
  • 7.3.2. Germany Psoriatic Arthritis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
  • 7.3.3. United Kingdom Psoriatic Arthritis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
  • 7.3.4. Italy Psoriatic Arthritis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
  • 7.3.5. Spain Psoriatic Arthritis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Psoriatic Arthritis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Psoriatic Arthritis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
  • 8.3.2. India Psoriatic Arthritis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
  • 8.3.3. South Korea Psoriatic Arthritis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
  • 8.3.4. Japan Psoriatic Arthritis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
  • 8.3.5. Australia Psoriatic Arthritis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration

9. South America Psoriatic Arthritis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Psoriatic Arthritis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
  • 9.3.2. Argentina Psoriatic Arthritis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
  • 9.3.3. Colombia Psoriatic Arthritis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration

10. Middle East and Africa Psoriatic Arthritis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Psoriatic Arthritis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
  • 10.3.2. Saudi Arabia Psoriatic Arthritis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
  • 10.3.3. UAE Psoriatic Arthritis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global Psoriatic Arthritis Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. AbbVie Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Amgen Inc.
• 16.3. Johnson & Johnson Services, Inc.
• 16.4. Bristol-Myers Squibb Company
• 16.5. Novartis AG
• 16.6. Eli Lilly and Company
• 16.7. Pfizer, Inc.
• 16.8. UCB S.A.

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료